Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients

Glioma Clinical Trial

Official title:

Is VEGF a Useful Serum Biomarker for Patients Diagnosed With Meningioma or Glioma?

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00985036
• Other study ID #: MGH-VEGF-1
• Status: Withdrawn
• Phase: N/A
• First received: September 25, 2009
• Last updated: April 20, 2012
• Start date: September 2009
• Est. completion date: January 2012

Study information

• Verified date: April 2012
• Source: Marquette General Health System
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Objectives: This study is looking at the level of vascular endothelial growth factor (VEGF) circulating in the blood stream of patients diagnosed with either a meningioma or a glioma. The questions that will be addressed include:

1. Can VEGF level alert us to tumor progression or recurrence before MRI changes occur?

2. Is the VEGF level an indicator of the response to treatment?

3. Does the VEGF level correlate with tumor histology and behavior?

4. Is there a relationship between VEGF level and outcome?

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 2012
• Est. primary completion date: September 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• any patient presenting with glioma or meningioma

Exclusion Criteria:

• a different type of brain tumor

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Glioma
• Meningioma

Intervention

Procedure:
• Blood test
an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test

Locations

Country	Name	City	State
United States	Marquette General Hospital	Marquette	Michigan

Sponsors (2)

Lead Sponsor	Collaborator
Marquette General Health System	Upper Michigan Brain Tumor Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine if VEGF levels correlate with tumor progression or recurrence		every one to three months	No
Secondary	Determine if the VEGF level is an indicator of the response to treatment.		Every one to three months	No
Secondary	Determine if the VEGF level correlates with tumor histology and behavior.		Every one to three months	No
Secondary	Determine if there is a relationship between VEGF level and outcome.		Every one to three months	No